Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access
- Conditions
- Implantable Defibrillator
- Registration Number
- NCT02117414
- Lead Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Brief Summary
The purpose of the Evera MRI™ study is to confirm safety and efficacy of the Evera MRI ICD (Implantable cardioverter-defibrillator) System in the clinical MRI (Magnetic Resonance Imaging) environment when subjects receive MRI scans without positioning restrictions (MRI scans may occur anywhere on the body).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 275
- Subjects who are indicated for implantation of an ICD at the time of study enrollment.
- Subjects who are able to undergo a pectoral implant.
- Subjects who are receiving an ICD for the first time.
- Subjects who are able and willing to undergo elective MRI scanning without sedation.
- Subjects who are geographically stable and available for follow-up at the study site for the length of the study.
- Subjects who are at least 18 years of age (or older, if required by local law).
- Subjects with a history of significant tricuspid valvular disease .
- Subjects for whom a single dose of 1.0mg dexamethasone sodium phosphate and/or dexamethasone acetate may be contraindicated.
- Subjects who require a legally authorized representative to obtain informed consent.
- Subjects undergoing device upgrades, change-outs, lead extractions, and/or lead or device revisions.
- Subjects with abandoned or capped leads.
- Subjects who require an indicated MRI scan, other than those specifically described in the Evera MRI™ study, before the one-month post-MRI/waiting period follow-up (approximately 4 months post-implant).
- Subjects with a non-MRI compatible device (such as neurostimulators) or material implant (e.g., non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys).
- Subjects with medical conditions that preclude the testing required by the study protocol or limit study participation.
- Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the Evera MRI™ study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
- Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within seven (7) days prior to device implant.
- Subjects with exclusion criteria required by local law (e.g., age, breastfeeding).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method MRI-related Events MRI procedure to 1-month post-MRI Number of patients free of MRI-related events. Events include MRI-related complications, sustained tachyarrhythmia, and MRI-related loss of pacing ability.
Ventricular Pacing Capture Threshold (VPCT) Pre-MRI/Waiting Period visit to 1-month post-MRI/Waiting Period visit Number of successful patients, where success is defined as not increasing VPCT by more than 0.5V from pre-MRI/waiting to one month post.
Ventricular Sensing Amplitude (R-wave) Pre-MRI/Waiting Period visit to 1-month post-MRI/Waiting Period visit Number of successful patients who do not experience a decrease in ventricular sensing amplitude of \>50% from the pre-MRI/waiting period to the one month post-MRI/waiting period, or a one month post-MRI/waiting value \<3mV accompanied by a decrease of \>25% from the pre-MRI/waiting period to the one month post-MRI/waiting period.
- Secondary Outcome Measures
Name Time Method System-related Complications Implant to 4 months post-implant Number of subjects free of a system-related complication. The system includes the ICD and lead(s) attached to it.
RV Defibrillation Impedance 1-month post-MRI/Waiting Period visit Number of subjects whose RV defibrillation impedance at the one-month post-MRI/waiting period visit is between 20 and 100 ohms
Superior Vena Cava (SVC) Defibrillation Impedance 1-month post-MRI/Waiting Period visit Number of subjects whose SVC defibrillation impedance at the one-month post-MRI/waiting period visit is between 20 and 100 ohms
Atrial Pacing Capture Threshold (APCT) Pre-MRI/Waiting Period visit to 1-month post-MRI/Waiting Period visit Number of successful patients, where success is defined as not increasing APCT by more than 0.5V from pre-MRI/waiting to one month post.
Atrial Sensing Amplitude MRI/waiting visit to 1-month post-MRI/Waiting visit Number of successful patients, where success is defined as not decreasing atrial sensing amplitude by more than 50% from pre-MRI/waiting to one month post.
Trial Locations
- Locations (42)
Central Coast Cardiology
🇺🇸Salinas, California, United States
Stanford Hospitals & Clinics
🇺🇸Stanford, California, United States
Hartford Hospital
🇺🇸Hartford, Connecticut, United States
Orlando Health
🇺🇸Orlando, Florida, United States
Prairie Education & Research Cooperative (Springfield IL)
🇺🇸Springfield, Illinois, United States
Iowa Heart
🇺🇸West Des Moines, Iowa, United States
Washington Hospital Center
🇺🇸Washington DC, Maryland, United States
DLP Upper Michigan Cardiovascular Associates PC
🇺🇸Marquette, Michigan, United States
Park Nicollet Methodist Hospital
🇺🇸Saint Louis Park, Minnesota, United States
United Heart and Vascular Clinic
🇺🇸Saint Paul, Minnesota, United States
Scroll for more (32 remaining)Central Coast Cardiology🇺🇸Salinas, California, United States